Table 1

Indirect comparisons between biologicals in the two populations of patients with rheumatoid arthritis (RA)

ComparisonsBiological 1Biological 2
RA active despite methotrexate
1All TNF blockers*All ‘non-anti-TNF biologicals’
2All TNF blockers*Rituximab16–18
3All TNF blockers*Abatacept7 19 20
4All TNF blockers*Tocilizumab21
5Rituximab16–18Abatacept7 19 20
6Rituximab16–18Tocilizumab21
7Abatacept7 19 20Tocilizumab21
RA with inadequate response to anti-TNF
8Tocilizumab24Rituximab17 22
9Tocilizumab24Abatacept23
10Abatacept23Rituximab17 22
11Tocilizumab24Golimumab25
12Rituximab17 22Golimumab25
13Abatacept23Golimumab25
  • * Infliximab with the two doses (3 and 10 mg/kg) pooled7 8 plus etanercept9 plus adalimumab10,,12 plus certolizumab13 14 plus golimumab.15

  • All ‘non-anti-TNF biologicals’ means rituximab,16,,18 abatacept7 19 20 and tocilizumab.21

  • TNF, tumour necrosis factor.